An FDA Panel Backed a Blood Test for 50+ Cancers. Here's What That Vote Actually Means
An advisory committee narrowly endorsed GRAIL's Galleri multi-cancer blood test. The underlying study measured how well it detects cancer — not whether finding cancer this way saves lives.
Singularity Wellness Editorial · 2026-10-17 · 4 min read
An FDA Panel Backed a Blood Test for 50+ Cancers. Here's What That Vote Actually Means
On September 23, 2026, an FDA advisory committee reviewed GRAIL's Galleri multi-cancer early detection blood test, which screens for more than 50 cancer types. The panel voted unanimously on safety but split 6-4 on effectiveness and 7-2 (with one abstention) on whether benefits outweigh risks; the FDA has not approved the test and expects a decision in the coming months. The vote coincided with the PATHFINDER 2 study in Nature Medicine (35,878 adults 50+), which measured detection performance when the test was added to standard screening — not whether earlier detection reduces late-stage disease or deaths. The central limitation: in PATHFINDER 2 the test flagged only a minority of the cancers diagnosed in the study (an episode sensitivity of 39.3%), a positive result requires further diagnostic workup, and the test is not a replacement for standard screening.
On September 23, 2026, an FDA advisory committee — the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee — reviewed GRAIL's Galleri test, a blood test that looks for DNA shed by cancers and is designed to screen for more than 50 cancer types. The headline is that the panel backed it. The more useful story is how narrowly, and on what evidence.
The panel's ten voting members were unanimous that the test is safe. On effectiveness they split 6 to 4 in favor, and on whether benefits outweigh risks they voted 7 to 2, with one abstention. The panel endorsed approval, but this is not a final decision — the FDA has not approved the test and is expected to decide in the coming months. One member who voted no on effectiveness, the National Cancer Institute's Dr. Stanley Lipkowitz, called the test 'transformative' while urging regulators to be 'more critical' before approving it. A split like that reflects a real debate about what the evidence proves.
What PATHFINDER 2 Measured — and What It Didn't
The review landed alongside the PATHFINDER 2 study in Nature Medicine, which enrolled 35,878 adults aged 50 and older and measured the test's performance and safety when added to standard recommended screening. That framing matters: the study measured how well the test detects cancer, not whether detecting cancer this way leads to fewer deaths or less late-stage disease.
The detection rate was about 0.54%. Of those enrolled, 287 had a positive signal and 173 were diagnosed with cancer, giving a positive predictive value of 60.3% — meaning a positive result corresponded to an actual cancer diagnosis about 60% of the time in this group. Specificity was 99.64%, and GRAIL cites a false-positive rate of roughly 0.4%, or about 1 in 250. Among newly detected cancers, 53.0% were stage I-II and 70.9% were stage I-III, suggesting the test often flags disease relatively early.
The Number That Keeps It Honest
Sensitivity — how reliably a test catches cancers that are actually present — is where expectations have to be managed, and it has to be quoted precisely. PATHFINDER 2's own figure is 'episode sensitivity': the share of cancer-diagnosed episodes in which the test returned a positive signal. That figure was 39.3% across all cancers, rising to 69.8% within a prespecified subgroup of 12 cancer types. In plain terms, across the full range of cancers the test did not flag the majority of those actually diagnosed during the study. A negative result therefore does not mean cancer is absent; it means no signal was detected this time.
A word on the numbers themselves: different sensitivity figures circulate for multi-cancer tests because they are measured over different cancer types, stages and definitions, and they are not interchangeable. We quote only PATHFINDER 2's own episode-sensitivity figures here rather than compare them to a headline percentage whose definition we can't pin down — which is itself part of reading a diagnostic claim honestly.
PATHFINDER 2 measured detection performance, not clinical outcomes such as reduced mortality. This is education, not medical advice: Singularity Wellness does not offer, order, endorse, or recommend this or any test, and nothing here is a suggestion to get — or to skip — any screening. Those decisions belong with a qualified clinician.
The practical cautions follow from the numbers. A positive result requires further diagnostic testing to locate any cancer. The test does not detect all cancers and does not predict future genetic cancer risk. Clinicians have also flagged a behavioral risk: a reassuring negative could lead someone to skip the standard screenings — colonoscopy, mammography — that remain the proven tools. It is not recommended for people 21 and under, those undergoing cancer treatment, or pregnant women.
A test's value depends on what it has been proven to change, not just on what it can detect.
The Framework View
This is the Measure and Understand stages of our framework in miniature. More testing is not automatically better care, and a new test's worth is measured not by how much it can detect but by whether acting on what it detects actually improves outcomes. For multi-cancer early detection, that is precisely the open question — which is why a narrow advisory vote, not a victory lap, is the honest way to report it.